Initial Gap Analysis on Standards Development

Presentation for HL7 International Work Group Biomedical Research & Regulation (BR&R)
Tuesday 22 September 2020 – Q2

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
Making IDMP and related standards and terminologies work across the landscape of implementation
Initial Gap Analysis – through workshops, wish lists, and use cases from UNICOM participants

► Use cases:
  ▶ ePrescription
  ▶ Clinical Processes (IPS, Medication Lists, etc.)
  ▶ Adverse Events (reporting to the authorities and beyond)
  ▶ Medication Errors
  ▶ Supply Chain Management

► Audience:
  ▶ Standards Developing Organizations

► Process:
  ▶ WP-1 to help identify the gaps, analyse their causes and possible solutions
  ▶ WP-1 to coordinate gap analysis across use cases and implementation domains
  ▶ WP-1 to hand over to the relevant SDO’s to address an interim and final solution
  ▶ SDO’s to discuss the identified gaps, with help from WP-1 and other informed experts
  ▶ SDO’s to formulate a response, including estimated timeline for final resolution
  ▶ WP-1 to disseminate this response an possible interim solutions within UNICOM
  ▶ WP-1 to inform and discuss with the Community of Expertise where appropriate

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 875299
Identified gaps across implementation domains – proposed next steps within HL7 International

► Evaluate impact and implement new manufactured item class / identifier (6.2.3.2)
► IDMP & FHIR alignment – cross-workgroup use cases and requirements definition (6.2.7.1)
► IDMP & FHIR alignment – resource harmonisation (6.2.7.3)
► Development of dispensation feedback message to prescriber including DCID (6.3.1.2)
► Logical model requirements from different use cases (6.3.6.x)
► Profile/IG updates for ePrescribing and eDispensing to align to IDMP (6.3.7.2)
► eDispensing related items and attributes in IDMP (6.4.1.1)
► Adverse Events processes, structured data and value sets (6.4.2.2)
► Medication Error processes, structured data and value sets (6.4.2.4)
► Guidance on the use of IDMP on mHealth apps (6.4.3.1)

► Bridging the regulatory and clinical domains – quality and maturity considerations (6.4.4.1)

► Use of IDMP to improve trust in AI through structured data (6.4.4.2)
Let’s work together to make this happen!